@article{01GT1EJJKM9VYM28XQ6T4QEW4R,
  abstract     = {{In an international cohort of 279 patients with hypoxemic influenza pneumonia, we identified 13 patients (4.6%) with autoantibodies neutralizing IFN-alpha and/or -omega, which were previously reported to underlie 15% cases of life-threatening COVID-19 pneumonia and one third of severe adverse reactions to live-attenuated yellow fever vaccine.

Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-alpha 2 alone (five patients) or with IFN-omega (eight patients) from a cohort of 279 patients (4.7%) aged 6-73 yr with critical influenza pneumonia. Nine and four patients had antibodies neutralizing high and low concentrations, respectively, of IFN-alpha 2, and six and two patients had antibodies neutralizing high and low concentrations, respectively, of IFN-omega. The patients' autoantibodies increased influenza A virus replication in both A549 cells and reconstituted human airway epithelia. The prevalence of these antibodies was significantly higher than that in the general population for patients <70 yr of age (5.7 vs. 1.1%, P = 2.2 x 10(-5)), but not >70 yr of age (3.1 vs. 4.4%, P = 0.68). The risk of critical influenza was highest in patients with antibodies neutralizing high concentrations of both IFN-alpha 2 and IFN-omega (OR = 11.7, P = 1.3 x 10(-5)), especially those <70 yr old (OR = 139.9, P = 3.1 x 10(-10)). We also identified 10 patients in additional influenza patient cohorts. Autoantibodies neutralizing type I IFNs account for similar to 5% of cases of life-threatening influenza pneumonia in patients <70 yr old.}},
  articleno    = {{e20220514}},
  author       = {{Zhang, Qian and Pizzorno, Andres and Miorin, Lisa and  Bastard, Paul and  Gervais, Adrian and  Le Voyer, Tom and  Bizien, Lucy and  Manry, Jeremy and  Rosain, Jeremie and  Philippot, Quentin and  Goavec, Kelian and  Padey, Blandine and  Cupic, Anastasija and  Laurent, Emilie and  Saker, Kahina and  Vanker, Martti and  Saerekannu, Karita and  Garcia-Salum, Tamara and  Ferres, Marcela and  Le Corre, Nicole and  Sanchez-Cespedes, Javier and  Balsera-Manzanero, Maria and  Carratala, Jordi and  Retamar-Gentil, Pilar and  Abelenda-Alonso, Gabriela and  Valiente, Adoracion and  Tiberghien, Pierre and  Zins, Marie and  Debette, Stephanie and  Meyts, Isabelle and Haerynck, Filomeen and  Castagnoli, Riccardo and  Notarangelo, Luigi D. and  Gonzalez-Granado, Luis I. and  Dominguez-Pinilla, Nerea and  Andreakos, Evangelos and  Triantafyllia, Vasiliki and  Rodriguez-Gallego, Carlos and  Sole-Violan, Jordi and  Ruiz-Hernandez, Jose Juan and  Rodriguez de Castro, Felipe and  Ferreres, Jose and  Briones, Marisa and  Wauters, Joost and  Vanderbeke, Lore and  Feys, Simon and  Kuo, Chen-Yen and  Lei, Wei-Te and  Ku, Cheng-Lung and  Tal, Galit and  Etzioni, Amos and  Hanna, Suhair and  Fournet, Thomas and  Casalegno, Jean-Sebastien and  Queromes, Gregory and  Argaud, Laurent and  Javouhey, Etienne and  Rosa-Calatrava, Manuel and  Cordero, Elisa and  Aydillo, Teresa and  Medina, Rafael A. and  Kisand, Kai and  Puel, Anne and  Jouanguy, Emmanuelle and  Abel, Laurent and  Cobat, Aurelie and  Trouillet-Assant, Sophie and  Garcia-Sastre, Adolfo and  Casanova, Jean-Laurent}},
  issn         = {{0022-1007}},
  journal      = {{JOURNAL OF EXPERIMENTAL MEDICINE}},
  keywords     = {{MYASTHENIA-GRAVIS PATIENTS,NEUTRALIZING ANTIBODIES,SEVERE COVID-19,INTERFERON,ALPHA,IMMUNITY,DETERMINANTS,INFECTION,ALLELES,BURDEN}},
  language     = {{eng}},
  number       = {{11}},
  pages        = {{29}},
  publisher    = {{Rockefeller Univ. Press}},
  title        = {{Autoantibodies against type I IFNs in patients with critical influenza pneumonia}},
  url          = {{http://doi.org/10.1084/jem.20220514}},
  volume       = {{219}},
  year         = {{2022}},
}

Altmetric

View in Altmetric

Web of Science

Times cited: